In situ-formed, tissue-adhesive co-gel composed of styrenated gelatin and styrenated antibody: potential use for local anti-cytokine antibody therapy on surgically resected tissues
Authors:
- Tatsuya ManabeTMTatsuya Manabe
- Takehisa MatsudaTMTakehisa Matsuda
- 1 December 2004
- journal article
- Published by Elsevier in Biomaterials
- Vol. 25 (27) , 5867-5873
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Novel therapeutic strategy for prevention of malignant tumor recurrence after surgery: Local delivery and prolonged release of adenovirus immobilized in photocured, tissue‐adhesive gelatinous matrixJournal of Biomedical Materials Research Part A, 2003
- Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseasesCytokine & Growth Factor Reviews, 2003
- Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implicationsSeminars in Oncology, 2002
- HPMA-hydrogels containing cytostatic drugsJournal of Controlled Release, 2002
- Monoclonal antibodies to target epidermal growth factor receptor–positive tumorsCancer, 2002
- Kringle 1–4 of Hepatocyte Growth Factor Inhibits Proliferation and Migration of Human Microvascular Endothelial CellsBiochemical and Biophysical Research Communications, 2000
- The effect of surgical wounding on tumour developmentEuropean Journal of Surgical Oncology, 1999
- Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancerCritical Reviews in Oncology/Hematology, 1999
- Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factorOncogene, 1998
- Recurrence after resection for ductal adenocarcinoma of the pancreasWorld Journal of Surgery, 1997